-
Aug 31, 2024 | 
immattersacp.org | Gianna Melillo |Charlotte Huff |Mary Schneider |ACP Internist
More than 430,000 people with end-stage renal disease (ESRD) are currently receiving in-center
hemodialysis treatment in the United States, and another 84,000 receive dialysis at home or at a nursing facility. But finding
out about treatment changes that happen during dialysis sessions can be a challenge
for primary care clinicians.
-
Jul 9, 2024 | 
friendsofcancerresearch.org | Mary Schneider
Industry and researchers welcomed a set of guidances from the US Food and Drug Administration (FDA) that seek to expand eligibility criteria in oncology clinical trials, but they pushed for clearer examples of how to apply the proposed flexibility, especially in early-stage trials. In April 2024, FDA issued a set of three draft guidance documents aimed at encouraging sponsors to expand the eligibility criteria in oncology clinical trials.
-
May 31, 2024 | 
immattersacp.org | Gianna Melillo |Charlotte Huff |Mary Schneider |ACP Internist
Homelessness and housing instability in the U.S. are increasingly being recognized
as taking a toll on physical and mental health. ACP recently issued a new position
paper calling on physicians and policymakers to address this crisis, working simultaneously
on the medical needs of patients with unstable housing and the lack of affordable
housing in America.
-
Apr 2, 2024 | 
cancertherapyadvisor.com | Mary Schneider
Research presented at the SGO 2024 Annual Meeting on Women’s Cancer highlighted the need for tailored treatment in ovarian cancer. Researchers presented data from trials exploring different combination therapies and dosing strategies.
-
Apr 2, 2024 | 
brnw.ch | Mary Schneider
Research presented at the SGO 2024 Annual Meeting on Women’s Cancer highlighted the need for tailored treatment in ovarian cancer. Researchers presented data from trials exploring different combination therapies and dosing strategies.
-
Mar 20, 2024 | 
tucson.com | Mary Schneider
I understand the voting public should be concerned about the cognitive ability of our leaders whether the mayor, representative, senator or president. I don’t remember the exact date/year my son died at age 47 but I do remember his age and the process of his passing. I don’t remember when was the last time I saw my best friend but I do remember the circumstances and what we experienced. I do remember who I have voted for and WHY I voted. I remember and KNOW that I love my country and WHY.
-
Feb 15, 2024 | 
friendsofcancerresearch.org | Mary Schneider
The US Food and Drug Administration (FDA) is several weeks late in issuing guidance on how and when drug and device companies must submit diversity action plans for clinical trial research. The Food and Drug Omnibus Reform Act (FDORA), passed by Congress in late December 2022, requires drug and device manufacturers to submit diversity action plans to the FDA outlining how they plan to enroll a diverse group of trial participants for phase 3 and other pivotal trials.
-
Jan 24, 2024 | 
ashpublications.org | Mary Schneider
February 2024
Ezintsha conducts community-based participant recruitment for a study of COVID-19 therapeutics. Photo courtesy of Ezintsha.
-
Dec 20, 2023 | 
cancertherapyadvisor.com | Mary Schneider
Studies presented at the ASH Annual Meeting 2023 have provided new insight into which patients with acute myeloid leukemia (AML) might benefit from more intensive treatment and which patients might fare better with less intensive therapy.
-
Dec 20, 2023 | 
brnw.ch | Mary Schneider
Studies presented at the ASH Annual Meeting 2023 have provided new insight into which patients with acute myeloid leukemia (AML) might benefit from more intensive treatment and which patients might fare better with less intensive therapy.
